pharma news today glp-1 obesity drugs Dozens of new are coming: these are the ones to watch Federal regulators on Wednesday approved
Description
Exploring the impact of sodium-glucose cotransporter-2 inhibitors on genitourinary toxicities in prostate cancer patients undergoing radiation therapy: a case study and discussion
31 This finding is regarded as of paramount importance in the long-term clinical care of patients with T2DM
Non-pharmacological interventions (weight loss 7-10%, Mediterranean diet, and physical activity) are represented as the therapeutic basis, together with pharmacological strategies under investigation or clinical use (THR- agonists, FGF-21 analogs, pan-PPAR modulators, GLP-1 RAs, GLP-1/GIP, SGLT-2 inhibitors, metformin, and statins)
(July 2023)
